Genolution

Genolution CapEx Growth

The Year-over-Year CapEx Growth of Genolution (225220.KQ) as of Nov 3, 2026 is -96.37 %. In the previous year, Year-over-Year CapEx Growth was 77.04 % — a change of -225.08% (lower).

CapEx Growth

-96.37 %

YoY

-225.08%

Last updated:

Year-over-Year CapEx Growth of Genolution is 2025 -96.37 % . Year-over-Year CapEx Growth of Genolution was 2024 77.04 % . It decreases by -225.08% lower compared to the previous year.

The Genolution CapEx Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx Growth
Date
CapEx Growth
Jan 1, 2018
239.32 KRW
Jan 1, 2019
7.56 KRW
Jan 1, 2020
176.12 KRW
Jan 1, 2021
-40.91 KRW
Jan 1, 2022
339.36 KRW
Jan 1, 2023
-69.47 KRW
Jan 1, 2024
77.04 KRW
Jan 1, 2025
-96.37 KRW
The Genolution CapEx Growth history
YEARCapEx GrowthYoY
-96.37 %-225.08%
77.04 %-210.90%
-69.47 %-120.47%
339.36 %-929.62%
-40.91 %-123.23%
176.12 %+2,229.65%
7.56 %-96.84%
239.32 %+68.72%
141.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Year-over-Year CapEx Growth of Genolution is -96.37 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year CapEx Growth Genolution since 2006 – with annual values, charts, and detailed analysis.

CapEx growth measures the percentage change in capital expenditures. Increasing CapEx can signal investment in future growth capacity.

To evaluate Year-over-Year CapEx Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year CapEx Growth.

Year-over-Year CapEx Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year CapEx Growth's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Genolution

All Key Metrics — Genolution